AR111941A1 - Derivados de pirimidina como moduladores del receptor de pge2 - Google Patents
Derivados de pirimidina como moduladores del receptor de pge2Info
- Publication number
- AR111941A1 AR111941A1 ARP180101315A ARP180101315A AR111941A1 AR 111941 A1 AR111941 A1 AR 111941A1 AR P180101315 A ARP180101315 A AR P180101315A AR P180101315 A ARP180101315 A AR P180101315A AR 111941 A1 AR111941 A1 AR 111941A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydroxy
- ring
- cycloalkyl
- alkoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1) para uso en el tratamiento de un cáncer, donde dicho cáncer se trata mediante la modulación de una respuesta inmune que comprende una reactivación del sistema inmune en el tumor; donde dicho compuesto se utiliza opcionalmente en combinación con uno o más agentes de quimioterapia y/o radioterapia y/o terapia dirigida; donde en compuestos de la fórmula (1) (R¹)ₙ representa uno, dos o tres sustituyentes opcionales en el anillo de fenilo, donde dichos sustituyentes se seleccionan independientemente de alquilo C₁₋₃, alcoxi C₁₋₃, -S-alquilo C₁₋₃, halógeno, fluoroalquilo C₁₋₃, fluoroalcoxi C₁₋₃, ciano, hidroxi, nitro, -CO-O-alquilo-C₁₋₃, -NRN⁷RN⁸ donde RN⁷ y RN⁸ representan independientemente hidrógeno o alquilo C₁₋₄, o RN⁷ y RN⁸ junto con el nitrógeno al que están unidos forman un anillo carbocíclico de 4 a 6 miembros; R³ representa hidrógeno, metilo o trifluorometilo; R⁴ᵃ y R⁴ᵇ representan independientemente hidrógeno, metilo, o R⁴ᵃ y R⁴ᵇ junto con el átomo de carbono al que están unidos representan un grupo cicloprop-1,1-diilo; R⁵ᵃ y R⁵ᵇ representan independientemente hidrógeno, metilo, o R⁵ᵃ y R⁵ᵇ junto con el átomo de carbono al que están unidos representan un grupo cicloprop-1,1-diilo; Ar¹ representa fenilo, o heteroarilo de 5 ó 6 miembros; dicho fenilo o heteroarilo de 5 ó 6 miembros es independientemente mono-, di- o tri-sustituido donde los sustituyentes se seleccionan independientemente de alquilo C₁₋₆; alcoxi C₁₋₄; fluoroalquilo C₁₋₃, donde dicho fluoroalquilo C₁₋₃ está opcionalmente sustituido con hidroxi; fluoroalcoxi C₁₋₃; halógeno; ciano; cicloalquilo C₃₋₆, donde dicho cicloalquilo C₃₋₆ está no sustituido o mono-sustituido con amino; cicloalquilo C₄₋₆ que contiene un átomo de oxígeno del anillo, donde dicho cicloalquilo C₄₋₆ que contiene un átomo de oxígeno del anillo no está sustituido o está mono-sustituido con hidroxi; cicloalquil C₃₋₆-oxi; hidroxi; -X¹-CO-RO¹, donde X¹ representa un enlace directo, alquileno C₁₋₃, alquileno-O-C₁₋₃-*, -NH-alquileno C₁₋₃-*, -S-CH₂-*, -CF₂-, -CH=CH-, -CHºCH-, -NH-CO-*, -CO-, o cicloalquileno C₃₋₅; donde los asteriscos indican el enlace que está unido al grupo -CO-RO¹; y RO¹ representa -OH; -O-alquilo C₁₋₄; -NH-SO₂-RS³ donde RS³ representa alquilo C₁₋₄, cicloalquilo C₃₋₆ donde el cicloalquilo C₃₋₆ opcionalmente contiene un átomo de oxígeno del anillo, cicloalquilo C₃₋₆-alquileno C₁₋₃ donde el cicloalquilo C₃₋₆ opcionalmente contiene un átomo de oxígeno del anillo, fluoroalquilo C₁₋₃, o -NH₂; -O-CH₂-CO-RO⁴, donde RO⁴ representa hidroxi, o alcoxi C₁₋₄, o N[alquilo C₁₋₄]₂; -O-CH₂-O-CO-RO⁵, donde RO⁵ representa alquilo C₁₋₄ o alcoxi C₁₋₄; -O-CH₂-CH₂-N[alquilo C₁₋₄]₂; o (5-metil-2-oxo-[1,3]dioxol-4-il)-metiloxi-; -CO-CH₂-OH; un compuesto de fórmula (2); 2-hidroxi-3,4-dioxo-ciclobut-1-enilo; hidroxi-alquilo C₁₋₄; dihidroxi-alquilo C₂₋₄; hidroxi-alcoxi C₂₋₄; alcoxi C₁₋₄-alcoxi C₂₋₄; -(CH₂)ʳ-CO-NRN³RN⁴ donde r representa el número entero 0 ó 1; y donde RN³ y RN⁴ representan independientemente hidrógeno, alquilo C₁₋₄, hidroxi-alquilo C₂₋₄, alquilo C₁₋₃-alquilo C₂₋₄, o hidroxi; -X²-NRN¹RN², donde X² representa -(CH₂)ₘ-, donde m representa el número entero 0 ó 1; o X² representa -O-CH₂-CH₂-*, donde el asterisco indica el enlace que está unido al grupo -NRN¹RN²; y donde RN¹ y RN² representan independientemente hidrógeno, alquilo C₁₋₄, alcoxi C₁₋₄-alquilo C₂₋₄, cicloalquilo C₃₋₆, o fluoroalquilo C₂₋₃; o RN¹ representa independientemente hidrógeno o alquilo C₁₋₄, y RN² representa independientemente -CO-H, -CO-alquilo C₁₋₃, -CO-alquileno C₁₋₃-OH, o -CO-O-alquilo C₁₋₃; o RN¹ y RN² junto con el nitrógeno al que están unidos forman un anillo saturado de 4, 5 ó 6 miembros que contiene opcionalmente un átomo de oxígeno del anillo o de azufre del anillo, donde dicho anillo no está sustituido, o está mono-sustituido con oxo en un átomo de carbono del anillo, o disustituido con oxo en un átomo de azufre del anillo; -NH-CO-NRN⁵RN⁶ donde RN⁵ y RN⁶ representan independientemente hidrógeno o alquilo C₁₋₃; -SO₂-RS¹ donde RS¹ representa, hidroxi, alquilo C₁₋₄, o NRN⁷RN⁸ donde RN⁷ y RN⁸ representan independientemente hidrógeno o alquilo C₁₋₃; -S-RS² donde RS² representa alquilo C₁₋₄, o cicloalquilo C₃₋₆ que contiene opcionalmente un átomo de oxígeno del anillo; (CH₂)q-HET¹, donde q representa el número entero 0, 1 ó 2; y donde HET¹ representa 5-oxo-4,5-dihidro-[1,2,4]oxadiazol-3-ilo, 3-oxo-2,3-dihidro-[1,2,4]oxadiazol-5-ilo, o 5-tioxo-4,5-dihidro-[1,2,4]oxadiazol-3-ilo; -(CH₂)ₚ-HET, donde p representa el número entero 0 ó 1; y donde HET representa un heteroarilo de 5 ó 6 miembros, donde dicho heteroarilo de 5 ó 6 miembros está no sustituido, o mono- o di-sustituido, donde los sustituyentes se seleccionan independientemente de alquilo C₁₋₄, alcoxi C₁₋₄, -COOH, hidroxi, hidroxi-alquilo C₁₋₃, cicloalquilo C₃₋₅ que contiene opcionalmente un átomo de oxígeno del anillo, o NRN⁹RN¹⁰ donde RN⁹ y RN¹⁰ representan independientemente hidrógeno, alquilo C₁₋₃ o hidroxi-alquilo C₂₋₄; o Ar¹ representa heteroarilo bicíclico de 8 a 10 miembros; donde dicho heteroarilo bicíclico de 8 a 10 miembros es independientemente no sustituido, mono-, o di-sustituido, donde los sustituyentes se seleccionan independientemente de alquilo C₁₋₄; alcoxi C₁₋₄; fluoroalquilo C₁₋₃; fluoroalcoxi C₁₋₃; halógeno; ciano; hidroxi, o -alquileno C₀₋₃-COORO² donde RO² representa hidrógeno o alquilo C₁₋₄; o Ar¹ representa un grupo de la estructura de fórmula (3) donde el anillo (B) representa un anillo no aromático de 5 ó 6 miembros fusionado al grupo fenilo, donde el anillo (B) comprende uno o dos heteroátomos seleccionados independientemente de nitrógeno y oxígeno; donde dicho anillo (B) es independientemente no sustituido, mono-, o di-sustituido, donde los sustituyentes se seleccionan independientemente de oxo, alquilo C₁₋₆ y -alquileno C₀₋₃-COORO³ donde RO³ representa hidrógeno o alquilo C₁₋₃; o una sal aceptable para uso farmacéutico del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2017062031 | 2017-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR111941A1 true AR111941A1 (es) | 2019-09-04 |
Family
ID=62186480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180101315A AR111941A1 (es) | 2017-05-18 | 2018-05-17 | Derivados de pirimidina como moduladores del receptor de pge2 |
Country Status (32)
Country | Link |
---|---|
US (1) | US11712438B2 (es) |
EP (1) | EP3625222B1 (es) |
JP (1) | JP7159214B2 (es) |
KR (1) | KR102632028B1 (es) |
CN (1) | CN110612296A (es) |
AR (1) | AR111941A1 (es) |
AU (1) | AU2018269666B2 (es) |
BR (1) | BR112019024109A2 (es) |
CA (1) | CA3060597A1 (es) |
CL (1) | CL2019003275A1 (es) |
CO (1) | CO2019010578A2 (es) |
CR (1) | CR20190559A (es) |
CY (1) | CY1124608T1 (es) |
DK (1) | DK3625222T3 (es) |
EA (1) | EA201992676A1 (es) |
ES (1) | ES2893452T3 (es) |
HR (1) | HRP20211533T1 (es) |
HU (1) | HUE056080T2 (es) |
IL (1) | IL270623B2 (es) |
LT (1) | LT3625222T (es) |
MA (1) | MA49126B1 (es) |
MX (1) | MX2019013718A (es) |
PE (1) | PE20191814A1 (es) |
PH (1) | PH12019502563A1 (es) |
PL (1) | PL3625222T3 (es) |
PT (1) | PT3625222T (es) |
RS (1) | RS62440B1 (es) |
SG (1) | SG11201908729UA (es) |
SI (1) | SI3625222T1 (es) |
TW (1) | TWI765041B (es) |
UA (1) | UA125123C2 (es) |
WO (1) | WO2018210994A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
TW201900180A (zh) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 嘧啶衍生物 |
CA3063632A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
MA49128A (fr) | 2017-05-18 | 2021-03-17 | Idorsia Pharmaceuticals Ltd | Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2 |
CA3086925A1 (en) | 2018-01-05 | 2019-07-11 | Ichan School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
EP3768267A4 (en) | 2018-03-20 | 2022-04-20 | Icahn School of Medicine at Mount Sinai | KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE |
WO2020142486A1 (en) * | 2018-12-31 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
KR20230107228A (ko) | 2020-11-13 | 2023-07-14 | 오노 야꾸힝 고교 가부시키가이샤 | Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료 |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
CA2402099C (en) | 2000-03-24 | 2011-04-26 | Pharmagene Laboratories Ltd. | Methods for the treatment of primary headache disorders using prostanoid ep4 receptor antagonists, and assays for agents for such treatment |
HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
GB0031295D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
BR0309305A (pt) | 2002-04-12 | 2005-02-15 | Pfizer | Compostos de imidazol como agentes antiinflamatórios e analgésicos |
MXPA04009960A (es) | 2002-04-12 | 2004-12-13 | Pfizer | Compuestos de pirazol como agentes anti-inflamatorios y analgesicos. |
WO2003099857A1 (en) | 2002-05-23 | 2003-12-04 | Theratechnologies Inc. | Antagonistic peptides of prostaglandin e2 receptor subtype ep4 |
KR101094003B1 (ko) | 2003-01-29 | 2011-12-15 | 아스터랜드 유케이 리미티드 | Ep4 수용체 길항제 |
MXPA06002001A (es) | 2003-08-26 | 2006-06-20 | Teijin Pharma Ltd | Derivados pirrolopirimidinona. |
ES2441206T3 (es) | 2003-09-03 | 2014-02-03 | Raqualia Pharma Inc. | Compuestos de fenil o piridilamida como antagonistas de la prostaglandina E2 |
WO2005026129A1 (en) | 2003-09-15 | 2005-03-24 | Gpc Biotech Ag | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
CA2565660C (en) | 2004-05-04 | 2009-11-03 | Pfizer Inc. | Ortho substituted aryl or heteroaryl amide compounds |
JP4054368B2 (ja) | 2004-05-04 | 2008-02-27 | ファイザー株式会社 | 置換メチルアリール又はヘテロアリールアミド化合物 |
HN2005000795A (es) | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
ATE533766T1 (de) | 2005-05-19 | 2011-12-15 | Merck Canada Inc | Chinolinderivate als ep4-antagonisten |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
AR060403A1 (es) | 2006-04-12 | 2008-06-11 | Sanofi Aventis | Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2 |
JP5244091B2 (ja) | 2006-04-24 | 2013-07-24 | メルク カナダ インコーポレイテッド | Ep4受容体アンタゴニストとしてのインドールアミド誘導体 |
US7705035B2 (en) | 2006-06-12 | 2010-04-27 | Merck Frosst Canada Ltd. | Indoline amide derivatives as EP4 receptor ligands |
US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
PT2044056E (pt) | 2006-07-14 | 2012-12-05 | Novartis Ag | Derivados de pirimidina como inibidores de alk-5 |
US8969394B2 (en) | 2006-08-11 | 2015-03-03 | Merck Frosst Canada Ltd. | Thiophenecarboxamide derivatives as EP4 receptor ligands |
WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
CA2679175C (en) | 2007-02-26 | 2015-01-13 | Merck Frosst Canada Ltd. | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists |
KR20090122931A (ko) | 2007-03-26 | 2009-12-01 | 아스테라스 세이야쿠 가부시키가이샤 | 오르니틴 유도체 |
JP2010522218A (ja) | 2007-03-26 | 2010-07-01 | メルク フロスト カナダ リミテツド | Ep4受容体アンタゴニストとしてのナフタレン及びキノリンスルホニル尿素誘導体 |
EP2014657A1 (de) * | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidine als Modulatoren des EP2-Rezeptors |
EP2172447A4 (en) | 2007-07-03 | 2011-08-24 | Astellas Pharma Inc | amide |
KR20100090772A (ko) | 2007-10-12 | 2010-08-17 | 인게니움 파르마코이티칼스 게엠베하 | 단백질 키나제 억제제 |
US8598202B2 (en) | 2008-02-19 | 2013-12-03 | Janssen Pharmaceutica Nv | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
DK2565191T3 (da) | 2008-05-14 | 2014-11-10 | Astellas Pharma Inc | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexancarboxylsyrederivater som EP4-receptorantagonister der er anvendelige til behandlingen af kronisk nyresvigt eller diabetisk nephropati |
US20130225528A1 (en) | 2008-05-21 | 2013-08-29 | Ariad Pharmaceuticals, Inc. | Phosphorus Derivatives as Kinase Inhibitors |
WO2010019796A1 (en) | 2008-08-14 | 2010-02-18 | Chemietek, Llc | Heterocyclic amide derivatives as ep4 receptor antagonists |
GB2474813B (en) | 2008-09-19 | 2014-05-28 | Biotechnology Res Corp Ltd | Triterpenoid compounds and methods of use thereof |
WO2010034110A1 (en) | 2008-09-25 | 2010-04-01 | Merck Frosst Canada Ltd. | Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists |
WO2011022348A1 (en) | 2009-08-18 | 2011-02-24 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid amide hydrolase |
EP2504008A1 (en) | 2009-11-23 | 2012-10-03 | Lexicon Pharmaceuticals, Inc. | Methods and assays for the treatment of irritable bowel syndrome |
JP5607241B2 (ja) | 2010-05-21 | 2014-10-15 | ケミリア・エービー | 新規ピリミジン誘導体 |
ES2610185T3 (es) | 2010-09-21 | 2017-04-26 | Eisai R&D Management Co., Ltd. | Composición farmacéutica |
KR101857310B1 (ko) | 2010-09-29 | 2018-05-11 | 가부시키가이샤 에누비 켄코우겡큐쇼 | 인간 프로스타글란딘 e2 수용체 ep4 에 대한 항체 |
WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
JP2013542967A (ja) | 2010-11-17 | 2013-11-28 | ノバルティス アーゲー | 3−(アミノアリール)−ピリジン化合物 |
ES2545110T3 (es) | 2010-12-10 | 2015-09-08 | Rottapharm Biotech S.R.L. | Derivados de piridinamida como antagonistas del receptor EP4 |
WO2012103071A2 (en) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
AU2012230229A1 (en) | 2011-03-24 | 2013-10-10 | Noviga Research Ab | Novel pyrimidine derivatives |
WO2012149528A1 (en) | 2011-04-29 | 2012-11-01 | Exelixis, Inc. | Inhibitors of inducible form of 6-phosphofructose-2-kinase |
WO2012177618A1 (en) | 2011-06-20 | 2012-12-27 | Emory University | Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto |
PL2729445T3 (pl) | 2011-07-04 | 2016-04-29 | Rottapharm Biotech Srl | Cykliczne pochodne aminowe jako antagoniści receptora EP4 |
EP2554662A1 (en) | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Methods of treatment of retinal degeneration diseases |
WO2013090552A1 (en) | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
PT2841428T (pt) | 2012-04-24 | 2018-11-29 | Vertex Pharma | Inibidores de adn-pk |
AR091429A1 (es) | 2012-06-29 | 2015-02-04 | Lilly Co Eli | Compuestos de fenoxietil piperidina |
TWI572597B (zh) | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基-苯甲酸化合物 |
EP2711364A1 (en) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer |
US9604937B2 (en) | 2012-11-27 | 2017-03-28 | Thomas Helledays Stiftelse For Medicinsk Forskning | Pyrimidine-2,4-diamine derivatives for treatment of cancer |
UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
EP2765128A1 (en) | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫-1h-異喹啉化合物 |
CN105263924B (zh) | 2013-05-30 | 2018-10-19 | 爱杜西亚制药有限公司 | Cxcr7受体调节剂 |
MX369804B (es) | 2013-06-12 | 2019-11-21 | Kaken Pharma Co Ltd | Derivado de 4-alquinil imidazol y medicamento que los comprende como ingrediente activo. |
AU2014315457B2 (en) | 2013-09-04 | 2018-05-10 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
ES2788848T3 (es) | 2013-09-06 | 2020-10-23 | Aurigene Discovery Tech Ltd | Derivados de 1,2,4-oxadiazol como inmunomoduladores |
WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
SI3057959T1 (en) * | 2013-10-17 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | DNA-PK INHIBITORS |
CN105814036B (zh) | 2013-10-17 | 2018-10-26 | 沃泰克斯药物股份有限公司 | 作为dna-pk抑制剂的共晶 |
ES2651858T3 (es) | 2013-12-17 | 2018-01-30 | Eli Lilly & Company | Derivados de amina cíclica de fenoxietilo y su actividad como moduladores del receptor EP4 |
CA2929562A1 (en) | 2013-12-17 | 2015-06-25 | Eli Lilly And Company | Dimethylbenzoic acid compounds |
TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ep4配體之新穎苯并咪唑衍生物 |
TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
EP3137074B1 (en) | 2014-04-29 | 2020-08-05 | Emory University | Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto |
JP6787792B2 (ja) | 2014-05-23 | 2020-11-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がんの処置のための併用治療 |
CA2948601A1 (en) | 2014-06-04 | 2015-12-10 | Thomas Helledays Stiftelse For Medicinsk Forskning | Mth1 inhibitors for treatment of inflammatory and autoimmune conditions |
PE20170268A1 (es) | 2014-06-19 | 2017-04-21 | Ariad Pharma Inc | Compuestos de heteroarilo para la inhibicion de cinasa |
WO2016021742A1 (en) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
TWI812496B (zh) | 2015-01-09 | 2023-08-11 | 日商小野藥品工業股份有限公司 | 三環性螺化合物之用途 |
WO2017014323A1 (en) | 2015-07-23 | 2017-01-26 | Takeda Pharmaceutical Company Limited | 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists |
CN108473497B (zh) | 2015-10-16 | 2021-09-10 | 卫材R&D 管理有限公司 | Ep4拮抗剂 |
CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
AU2017295720B2 (en) | 2016-07-13 | 2021-07-22 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
PE20191787A1 (es) | 2017-05-18 | 2019-12-24 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos |
TW201900180A (zh) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 嘧啶衍生物 |
CA3063632A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
MA49128A (fr) | 2017-05-18 | 2021-03-17 | Idorsia Pharmaceuticals Ltd | Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2 |
-
2018
- 2018-05-17 ES ES18725222T patent/ES2893452T3/es active Active
- 2018-05-17 CR CR20190559A patent/CR20190559A/es unknown
- 2018-05-17 CN CN201880031321.4A patent/CN110612296A/zh active Pending
- 2018-05-17 PT PT18725222T patent/PT3625222T/pt unknown
- 2018-05-17 MA MA49126A patent/MA49126B1/fr unknown
- 2018-05-17 AU AU2018269666A patent/AU2018269666B2/en not_active Ceased
- 2018-05-17 TW TW107116759A patent/TWI765041B/zh not_active IP Right Cessation
- 2018-05-17 DK DK18725222.6T patent/DK3625222T3/da active
- 2018-05-17 LT LTEPPCT/EP2018/062862T patent/LT3625222T/lt unknown
- 2018-05-17 SI SI201830422T patent/SI3625222T1/sl unknown
- 2018-05-17 UA UAA201911975A patent/UA125123C2/uk unknown
- 2018-05-17 PL PL18725222T patent/PL3625222T3/pl unknown
- 2018-05-17 HU HUE18725222A patent/HUE056080T2/hu unknown
- 2018-05-17 WO PCT/EP2018/062862 patent/WO2018210994A1/en unknown
- 2018-05-17 KR KR1020197037298A patent/KR102632028B1/ko active IP Right Grant
- 2018-05-17 AR ARP180101315A patent/AR111941A1/es unknown
- 2018-05-17 SG SG11201908729U patent/SG11201908729UA/en unknown
- 2018-05-17 JP JP2019563491A patent/JP7159214B2/ja active Active
- 2018-05-17 HR HRP20211533TT patent/HRP20211533T1/hr unknown
- 2018-05-17 BR BR112019024109-4A patent/BR112019024109A2/pt unknown
- 2018-05-17 EP EP18725222.6A patent/EP3625222B1/en active Active
- 2018-05-17 IL IL270623A patent/IL270623B2/en unknown
- 2018-05-17 MX MX2019013718A patent/MX2019013718A/es unknown
- 2018-05-17 US US16/614,594 patent/US11712438B2/en active Active
- 2018-05-17 PE PE2019002396A patent/PE20191814A1/es unknown
- 2018-05-17 CA CA3060597A patent/CA3060597A1/en active Pending
- 2018-05-17 RS RS20211256A patent/RS62440B1/sr unknown
- 2018-05-17 EA EA201992676A patent/EA201992676A1/ru unknown
-
2019
- 2019-09-27 CO CONC2019/0010578A patent/CO2019010578A2/es unknown
- 2019-11-15 PH PH12019502563A patent/PH12019502563A1/en unknown
- 2019-11-15 CL CL2019003275A patent/CL2019003275A1/es unknown
-
2021
- 2021-10-19 CY CY20211100906T patent/CY1124608T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR111941A1 (es) | Derivados de pirimidina como moduladores del receptor de pge2 | |
AR111807A1 (es) | Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2 | |
AR111808A1 (es) | Derivados de pirimidina como moduladores del receptor de pge2 | |
AR111874A1 (es) | Derivados de pirimidina | |
AR108709A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
AR115885A1 (es) | Compuestos derivados de 1h-pirazolo[4,3-d]pirimidina como agonistas del receptor 7 tipo toll (tlr7) y su uso en combinación con un agente de inmunoterapia anticancerígeno | |
AR102204A1 (es) | Compuestos derivados de amino-alquilbenzotiazepinas | |
AR112348A1 (es) | Compuestos bicíclicos de pirazolo y triazolo como inhibidores de quinasas jak | |
AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
AR107714A1 (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
AR103064A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
PE20181304A1 (es) | Derivados de indol n-sustituidos como moduladores de los receptores de pge2 | |
AR110038A1 (es) | Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos | |
AR119657A1 (es) | Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos | |
AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
AR114369A1 (es) | Dinucleótidos cíclicos como agentes antineoplásicos | |
AR123848A1 (es) | Compuestos espiro heterocíclicos y métodos de uso | |
AR105975A1 (es) | Sulfonamidas tricílicas limitadas heterocíclicas como agentes contra el cáncer | |
AR114564A1 (es) | DERIVADOS DE 2,4,6,7-TETRAHIDRO-PIRAZOLO[3,4-D]PIRIMIDIN-ONA COMO MODULADORES DEL RECEPTOR C5a Y COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE | |
AR103414A1 (es) | Derivados de hidroxialquil-piperazina como moduladores del receptor cxcr3 | |
AR114465A1 (es) | Compuestos de pirazol sustituidos con heteroarilo y su utilización farmacéutica | |
AR113931A1 (es) | Tratamientos de combinación que comprenden la administración de 1h-pirazolo[4,3-b]piridinas | |
AR101798A1 (es) | Quinolinas herbicidas |